We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles.
- Authors
Campbell, Diahnn F.; Saenz, Rebecca; Bharati, Ila S.; Seible, Daniel; Liangfang Zhang; Esener, Sadik; Messmer, Bradley; Larsson, Marie; Messmer, Davorka
- Abstract
Introduction: Cancer vaccines have the potential to induce curative anti-tumor immune responses and better adjuvants may improve vaccine efficacy. We have previously shown that Hp91, a peptide derived from the B box domain in high-mobility group box protein 1 (HMGB1), acts as a potent immune adjuvant. Method: In this study, Hp91 was tested as part of a therapeutic vaccine against human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Results: Free peptide did not significantly augment immune responses but, when delivered in poly(D,L-lactic-coglycolic) acid nanoparticles (PLGA-NPs), robust activation of dendritic cells (DCs) and increased activation of HER2- specific T cells was observed in vitro. Vaccination of HER2/neu transgenic mice, a mouse breast cancer model that closely mimics the immune modulation and tolerance in some breast cancer patients, with Hp91-loaded PLGA-NPs enhanced the activation of HER2-specific cytotoxic T lymphocyte (CTL) responses, delayed tumor development, and prolonged survival. Conclusions: Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine.
- Subjects
IMMUNE response; EPIDERMAL growth factor receptors; LABORATORY mice; CANCER vaccines; ADJUVANT treatment of cancer; PEPTIDES; T cells
- Publication
Breast Cancer Research, 2015, Vol 17, Issue 1, p1
- ISSN
1465-5411
- Publication type
Article
- DOI
10.1186/s13058-015-0552-9